Rodrigo J Valderrábano1, Petra Buzkova2, Po-Yin Chang3, Neil A Zakai4, Howard A Fink5, John A Robbins6, Jennifer S Lee7, Joy Y Wu8. 1. Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, United States of America; University of Miami Miller School of Medicine, Miami, FL, United States of America. 2. Department of Biostatistics, University of Washington, United States of America. 3. Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, United States of America; School of Medicine, University of California, Davis, United States of America. 4. Department of Medicine and Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont. 5. GRECC, Veteran Affairs Health Care System, Minneapolis, MN, United States of America. 6. School of Medicine, University of California, Davis, United States of America. 7. Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, United States of America; Palo Alto Veteran Affairs Health Care System, Palo Alto, CA, United States of America. Electronic address: Jennifer.s.lee@stanford.edu. 8. Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, United States of America. Electronic address: jywu1@stanford.edu.
Abstract
PURPOSE: Osteoblasts and their precursors support hematopoiesis in the bone marrow. We hypothesized that declines in Hgb levels are associated with bone mineral density (BMD). METHODS: The Cardiovascular Health Study is a prospective longitudinal study that enrolled 5888 community-dwelling adults aged >65 years and measured hemoglobin twice, in 1989-90 and 1992-93, as well as BMD by dual-energy X-ray absorptiometry (DXA) in 1994-95. In a subset of 1513 men and women with a Hgb in 1992-93 and BMD, we used linear regression to estimate associations of Hgb (per standard deviation (SD)) with total hip (TH), lumbar spine (LS) and total body (TB) BMD, and used Poisson regression to estimate associations of anemia (in 1992-93; Hgb <13 g/dL in men; <12 g/dL in women) with "low BMD" defined as T-score less than -1 at the TH. In 1277 participants with Hgb measured on average 2.9 years apart and BMD, we used linear regression to estimate the associations of annualized change in Hgb with TH, LS and TB BMD. All models included age, sex, study-site, race, smoking, alcohol use, weight, height, steroid use, physical activity score, self-reported health, previous cardiovascular disease and prior anti-fracture medication use. RESULTS: No significant association was observed between Hgb, measured a mean 2.2 years prior to BMD, and BMD at the TH and LS in men (TH beta = -0.60 [x 10-2 g/cm2per 1.1 g/dL Hgb], 95% CI: -1.88 to 0.68; LS beta = -1.69, 95% CI: -3.83 to 0.45) or women (TH beta = -0.49 [x 10-2 g/cm2per 1.3 g/dL Hgb], 95% CI: -1.57 to 0.59; LS beta = -0.40, 95% CI: -2.57 to 1.76). Anemia was not observed to be significantly associated with low BMD in men (RR = 0.99, 95% CI: 0.72-1.40) nor women (RR = 0.98, 95% CI: 0.82-1.17). The mean change in Hgb was a loss of 0.06 g/dL/year (SD = 0.32). Change in Hgb was not observed to be significantly associated with BMD in men (TH beta = -0.55[x 10-2 g/cm2per 1 g/dL annualized Hgb change], 95% CI: -4.28 to 3.19; LS beta = 0.63, 95% CI: -5.38 to 6.65) or women (TH beta = 0.92, 95% CI: -1.96 to 3.79; LS beta = -1.77, 95% CI: -7.52 to 3.98). No significant association was observed between anemia and low bone density by T-score in men and women. CONCLUSIONS: These findings support neither the hypothesis that low Hgb prior to bone density or decreases in Hgb are associated with bone density in older community-dwelling adults nor the use of Hgb level as a case-finding tool to prompt BMD measurement.
PURPOSE: Osteoblasts and their precursors support hematopoiesis in the bone marrow. We hypothesized that declines in Hgb levels are associated with bone mineral density (BMD). METHODS: The Cardiovascular Health Study is a prospective longitudinal study that enrolled 5888 community-dwelling adults aged >65 years and measured hemoglobin twice, in 1989-90 and 1992-93, as well as BMD by dual-energy X-ray absorptiometry (DXA) in 1994-95. In a subset of 1513 men and women with a Hgb in 1992-93 and BMD, we used linear regression to estimate associations of Hgb (per standard deviation (SD)) with total hip (TH), lumbar spine (LS) and total body (TB) BMD, and used Poisson regression to estimate associations of anemia (in 1992-93; Hgb <13 g/dL in men; <12 g/dL in women) with "low BMD" defined as T-score less than -1 at the TH. In 1277 participants with Hgb measured on average 2.9 years apart and BMD, we used linear regression to estimate the associations of annualized change in Hgb with TH, LS and TB BMD. All models included age, sex, study-site, race, smoking, alcohol use, weight, height, steroid use, physical activity score, self-reported health, previous cardiovascular disease and prior anti-fracture medication use. RESULTS: No significant association was observed between Hgb, measured a mean 2.2 years prior to BMD, and BMD at the TH and LS in men (TH beta = -0.60 [x 10-2 g/cm2per 1.1 g/dL Hgb], 95% CI: -1.88 to 0.68; LS beta = -1.69, 95% CI: -3.83 to 0.45) or women (TH beta = -0.49 [x 10-2 g/cm2per 1.3 g/dL Hgb], 95% CI: -1.57 to 0.59; LS beta = -0.40, 95% CI: -2.57 to 1.76). Anemia was not observed to be significantly associated with low BMD in men (RR = 0.99, 95% CI: 0.72-1.40) nor women (RR = 0.98, 95% CI: 0.82-1.17). The mean change in Hgb was a loss of 0.06 g/dL/year (SD = 0.32). Change in Hgb was not observed to be significantly associated with BMD in men (TH beta = -0.55[x 10-2 g/cm2per 1 g/dL annualized Hgb change], 95% CI: -4.28 to 3.19; LS beta = 0.63, 95% CI: -5.38 to 6.65) or women (TH beta = 0.92, 95% CI: -1.96 to 3.79; LS beta = -1.77, 95% CI: -7.52 to 3.98). No significant association was observed between anemia and low bone density by T-score in men and women. CONCLUSIONS: These findings support neither the hypothesis that low Hgb prior to bone density or decreases in Hgb are associated with bone density in older community-dwelling adults nor the use of Hgb level as a case-finding tool to prompt BMD measurement.
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: Rodrigo J Valderrábano; Jennifer Lee; Li-Yung Lui; Andrew R Hoffman; Steven R Cummings; Eric S Orwoll; Joy Y Wu Journal: J Clin Endocrinol Metab Date: 2017-07-01 Impact factor: 5.958
Authors: L Jørgensen; T Skjelbakken; M-L Løchen; L Ahmed; A Bjørnerem; R Joakimsen; B K Jacobsen Journal: Osteoporos Int Date: 2009-12-03 Impact factor: 4.507
Authors: Anna Jovanovich; Petra Bùzková; Michel Chonchol; John Robbins; Howard A Fink; Ian H de Boer; Bryan Kestenbaum; Ronit Katz; Laura Carbone; Jennifer Lee; Gail A Laughlin; Kenneth J Mukamal; Linda F Fried; Michael G Shlipak; Joachim H Ix Journal: J Clin Endocrinol Metab Date: 2013-06-14 Impact factor: 5.958
Authors: H L Kristjansdottir; D Mellström; P Johansson; M Karlsson; L Vandenput; M Lorentzon; H Herlitz; C Ohlsson; U H Lerner; C Lewerin Journal: Osteoporos Int Date: 2020-12-11 Impact factor: 4.507